Late antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced?
| dc.contributor.author | Nourie, Nicole | |
| dc.contributor.author | Nassereddine, Hussein | |
| dc.contributor.author | Mouawad, Sarah | |
| dc.contributor.author | Chebbou, Louaa | |
| dc.contributor.author | Ghaleb, Rita | |
| dc.contributor.author | Abbas, Fatmeh Ibrahim | |
| dc.contributor.author | Azar, Hiba | |
| dc.contributor.department | Pathology and Laboratory Medicine | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T12:10:14Z | |
| dc.date.available | 2025-01-24T12:10:14Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | Background: Antibody-mediated rejection (AMR) was described in kidney transplant patients after viral infections, such as the cytomegalovirus. Very few cases were recently reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, probably in the context of lowering of immunosuppressive therapy. To date, no direct immunological link was proved to explain a connection between the coronavirus disease 19 (COVID-19) infection and antibody-mediated rejection (AMR) if it exists. Case presentation: Here we try to find this association by presenting the case of a low immunological risk patient who presented, six years post-transplant, with c4d negative antibody mediated rejection due to an anti-HLA-C17 de novo donor specific antibody (DSA) after contracting the coronavirus disease 19. The HLA-Cw17 activated the antibody-dependent cell-mediated cytotoxicity via the KIR2DS1 positive NK cells. Discussion and conclusions: This case report mayprove a direct role for COVID-19 infection in AMRs in the kidney transplantrecipients, leading us to closely monitor kidney transplant recipients,especially if they have “at-risk” donor antigens. © 2022, The Author(s). | |
| dc.identifier.doi | https://doi.org/10.1186/s12882-022-02713-x | |
| dc.identifier.eid | 2-s2.0-85125873294 | |
| dc.identifier.pmid | 35247969 | |
| dc.identifier.uri | http://hdl.handle.net/10938/32288 | |
| dc.language.iso | en | |
| dc.publisher | BioMed Central Ltd | |
| dc.relation.ispartof | BMC Nephrology | |
| dc.source | Scopus | |
| dc.subject | Antibody mediated rejection | |
| dc.subject | Case report | |
| dc.subject | Covid 19 | |
| dc.subject | Natural killers | |
| dc.subject | Antibodies | |
| dc.subject | Covid-19 | |
| dc.subject | Graft rejection | |
| dc.subject | Humans | |
| dc.subject | Kidney transplantation | |
| dc.subject | Male | |
| dc.subject | Middle aged | |
| dc.subject | Time factors | |
| dc.subject | Antibody | |
| dc.subject | Basiliximab | |
| dc.subject | Cd20 antigen | |
| dc.subject | Cd3 antigen | |
| dc.subject | Complement component c1q | |
| dc.subject | Complement component c3 | |
| dc.subject | Creatinine | |
| dc.subject | Donor specific antibody | |
| dc.subject | Hla antigen class 1 | |
| dc.subject | Hla c antigen | |
| dc.subject | Hla cw17 antigen | |
| dc.subject | Immunoglobulin | |
| dc.subject | Immunoglobulin m | |
| dc.subject | Mycophenolate mofetil | |
| dc.subject | Paracetamol | |
| dc.subject | Steroid | |
| dc.subject | Tacrolimus | |
| dc.subject | Unclassified drug | |
| dc.subject | Adult | |
| dc.subject | Antibody dependent cellular cytotoxicity | |
| dc.subject | Article | |
| dc.subject | Clinical article | |
| dc.subject | Complement deposition | |
| dc.subject | Computer assisted tomography | |
| dc.subject | Coronavirus disease 2019 | |
| dc.subject | Creatinine blood level | |
| dc.subject | Drug dose reduction | |
| dc.subject | Family history | |
| dc.subject | Fatigue | |
| dc.subject | Fever | |
| dc.subject | Focal glomerulosclerosis | |
| dc.subject | Ground glass opacity | |
| dc.subject | Hemodialysis | |
| dc.subject | Human | |
| dc.subject | Human tissue | |
| dc.subject | Immunoglobulin deposition | |
| dc.subject | Immunohistochemistry | |
| dc.subject | Kidney biopsy | |
| dc.subject | Kidney graft rejection | |
| dc.subject | Living donor | |
| dc.subject | Low drug dose | |
| dc.subject | Low risk patient | |
| dc.subject | Minimum plasma concentration | |
| dc.subject | Natural killer cell | |
| dc.subject | Plasma exchange | |
| dc.subject | Complication | |
| dc.subject | Immunology | |
| dc.subject | Time factor | |
| dc.title | Late antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced? | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1